Pre-Conference Workshops

Monday, March 4 | 10:30 am - noon (Registration Required to Attend)

PBMI is offering three pre-conference workshops the morning of the first day (all are from 10:30 am to noon).  Attendance is free but registration is required to attend.  You can sign up for a workshop during the conference registration process.

Lunch is included with each workshop and will be served at noon.

Workshop A

Specialty Partnership Leading to Better Outcomes

Timothy Carroll, PharmD, Director of Pharmacy Operations and Business Development
Nathaniel Varnum, RPh, MBA, Clinical Sales Executive
Reliance Rx

As a payor, PBM, or self-funded group, you should have a high level of support from your specialty pharmacy partner. This session sets out to inform on the minimum expectations that should define your relationship with your specialty pharmacy, and how these standards lead to better outcomes.

Topics to be discussed

  • Cutting edge partnership and specialty pharmacy team accessibility to support your team with items such as specialty-related questions, specialty pharmacy pipeline updates, and 340B implementation
  • Clinical programs, with a focus on empowering patients and promoting safe and effective use of products
  • Flexible reporting capabilities, including clinical, patient-reported, and employer-specific outcomes
  • How specialty pharmacy partnership can lead to cost savings, including how clinical review and close monitoring of new alternative products can bend the specialty trend

Workshop sponsored by  

Workshop B

Improving the Patient Experience: Reducing Friction in the Prescribing Process

Luke Forster-Broten, Manager, Product Innovation
Chris DiBlasi, Director of Product Innovation

Patients are looking for a better prescription experience and that starts with a better interaction with their provider. Today, many patients leave their doctor's office with a clear plan for how to take care of themselves. Yet, when they head to the pharmacy, they find out that their prescription is too expensive or that there is a delay in it’s fulfillment. This causes frustration for the patient and may ultimately result in the patient not getting the optimal drug or even choosing to forgo the therapy. In this session, you will explore today’s challenges with prescription delivery and how optimizing the prescribing decision within the provider workflow can alleviate friction for the patient downstream and improve speed to therapy.

Learning Objectives
  • Explore the most common challenges with prescription delivery in today’s e-prescribing environment, such as price transparency and medication reconciliation
  • Review how PBMs are working to solve today’s challenges, including formulary accessability
  • Identify value of using data intelligence at the point of care to reduce downstream medication delivery obstacles
Workshop sponsored by

Workshop C

An Outside the Box Approach to Controlling Pharmacy Spend and Utilization  

Kelsey Neystel, Benefits Analyst, Southwest Airlines
Donna Joyner, CPA, CGBA, Deputy Director, Public Education Employees' Health Insurance Plan Retirement Systems of Alabama
Diane E. Scott, CPA, CGMA, Chief Financial Officer, Public Education Employees' Health Insurance Plan Retirement Systems of Alabama
Renee Rayburg, RPh, Vice President of Specialty Clinical Consulting, Artemetrx

During this workshop, you will hear from two very different large employers facing increasing specialty drug spend challenges. While traditionally the focus has been to manage unit cost, one employer group has chosen to focus their efforts on managing both cost and utilization. Revisions to over 100 specialty PA’s incorporating more stringent criteria, measurable markers, and collection of documentation helped to decrease their trend from 39% to 0%. The second employer, frustrated at the news of an increasing specialty drug trend primarily driven by quarter over quarter increases in HIV spend, was in search of a strategy to better control costs. A closer look at their data revealed several high cost, low value drugs in their top 25. Utilizing a combination of strategies, one of which had not been used before, they achieved a -9.5% non-specialty drug trend and over $7M in savings as a result with minimal disruption and no negative effects on member experience.

Workshop sponsored by